Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866242 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00866242 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 20 participants.
The verdict
NCT00866242, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
Interventions
- BIOLOGICAL CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866242
The ClinicalTrials.gov registry entry for NCT00866242 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a is the first listed.
NCT00866242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866242 about?
NCT00866242 is a clinical study titled "Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb". The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.
What is the current status of trial NCT00866242?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00866242?
The interventions under investigation include: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT00866242?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.